MTA3 and pancreatic ductal adenocarcinoma: Notably, Wu et al. demonstrated that MTA3 mediates chemoresistance in pancreatic ductal adenocarcinoma by promoting gemcitabine resistance through epigenetic regulation of drug metabolism pathways (29).